Par Drugs & Chemicals Ltd
Par Drugs & Chemicals Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Par Drugs & Chemicals Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended 30th September 2026: Rs. 2,743.19 lakh.
As stated in Par Drugs & Chemicals Ltd's Q2 FY27 results statement · published 30 Oct 2026. Reported figures, not investment advice.
Based on Par Drugs & Chemicals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30th September 2026: Rs. 2,743.19 lakh (Page 5). EBITDA for the quarter ended 30-09-2026: Rs. 1,048.42 lakhs (calculated as Profit before tax Rs. 987.37 lakhs + Depreciation Rs. 94.35 lakhs + Finance costs Rs. 1.65 lakhs).
From Par Drugs & Chemicals Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.
How did Par Drugs & Chemicals' revenue grow in the September 2026 quarter?
- Revenue from operations for the quarter ended 30th September 2026: Rs. 2,743.19 lakh (Page 5).
- Revenue from operations for the quarter ended 30th September 2025: Rs. 5,470.53 lakh (Page 5).
- This shows a year-on-year decrease in quarterly revenue of approximately 49.9%.
- Half year to date (Sept 30, 2026) revenue from operations: Rs. 5,871.24 lakh vs Rs. 9,412.80 lakh for same period in 2025, indicating a similar decline.
What happened to Par Drugs & Chemicals' margins in Q2 FY27?
See what Par Drugs & Chemicals Ltd said on profitability & margins — free account, 30 seconds.
What capex is Par Drugs & Chemicals planning?
See what Par Drugs & Chemicals Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Par Drugs & Chemicals raising money or cutting debt?
See what Par Drugs & Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Par Drugs & Chemicals' order book?
See what Par Drugs & Chemicals Ltd said on order book & pipeline — free account, 30 seconds.
Par Drugs & Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹27 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Par Drugs & Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Par Drugs & Chemicals Ltd Q2 FY27 results?
Revenue from operations for the quarter ended 30th September 2026: Rs. 2,743.19 lakh (Page 5). EBITDA for the quarter ended 30-09-2026: Rs. 1,048.42 lakhs (calculated as Profit before tax Rs. 987.37 lakhs + Depreciation Rs. 94.35 lakhs + Finance costs Rs. 1.65 lakhs).
What is Par Drugs & Chemicals Ltd share price analysis?
Par Drugs & Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 10.2 with a market cap of ₹149 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Par Drugs & Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.